financetom
Business
financetom
/
Business
/
Marvell Technology Insider Sold Shares Worth $1,329,450, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Marvell Technology Insider Sold Shares Worth $1,329,450, According to a Recent SEC Filing
May 14, 2026 12:31 PM

03:03 PM EDT, 05/14/2026 (MT Newswires) -- Matthew J Murphy, Director, Chairman of the Board, and CEO, on May 13, 2026, sold 7,500 shares in Marvell Technology ( MRVL ) for $1,329,450. Following the Form 4 filing with the SEC, Murphy has control over a total of 739,397 common shares of the company, with 739,397 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1835632/000162828026034988/xslF345X05/wk-form4_1778785042.xml

Price: 183.71, Change: +5.76, Percent Change: +3.24

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Gaxos.ai Inc. Sells Gaming Assets to Game Foundry AI
Gaxos.ai Inc. Sells Gaming Assets to Game Foundry AI
Jun 24, 2026
Transaction streamlines operations and positions Gaxos to focus on revenue-generating, higher-margin opportunities Roseland, NJ, June 24, 2026 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ( GXAI ) (Gaxos or the Company), a company developing artificial intelligence applications across various high-growth sectors, today announced that it had completed the sale of its gaming assets, including its portfolio of mobile games and Gaxos Gaming...
Form 8.3
Form 8.3
Jun 24, 2026
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Form 8.3
Form 8.3
Jun 24, 2026
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Antares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis
Antares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis
Jun 24, 2026
June 24 (Reuters) - Antares Therapeutics said on Wednesday it entered a collaboration with Novartis that could be worth up to about $1.9 billion, aiming to develop therapies for historically hard-to-drug cancer targets. Here are some details of the deal: * Antares Therapeutics said it will receive $105 million upfront under the agreement with Novartis. * The biotech is also...
Copyright 2023-2026 - www.financetom.com All Rights Reserved